Last updated: October 18, 2026
Dovonex is the former brand name for calcipotriene, also called calcipotriol, a topical vitamin D analog used to treat plaque psoriasis. Leo Pharma commercialized Dovonex in multiple topical formulations, including cream, ointment, and scalp solution. The product’s core patent protection has expired, FDA-approved generic calcipotriene products compete in the United States, and combination products such as calcipotriene and betamethasone have reduced the commercial role of single-agent Dovonex.
Dovonex no longer has the financial profile of a protected branded medicine. Its market is mature, price-sensitive, and divided among generic calcipotriene, branded combination products, over-the-counter psoriasis products, phototherapy, and newer biologic treatments. Leo Pharma does not publicly disclose standalone Dovonex revenue, so the product’s historical and current financial trajectory must be assessed through regulatory status, generic availability, market structure, and the company’s portfolio disclosures.
What is Dovonex and how does calcipotriene work?
Dovonex contains calcipotriene, the synthetic form of calcipotriol used topically for plaque psoriasis. The drug regulates keratinocyte proliferation and differentiation through activity related to the vitamin D receptor. It is generally used on limited areas of psoriasis and is not interchangeable with systemic biologics or oral small-molecule therapies.
The principal Dovonex dosage forms were:
| Product |
Active ingredient |
Typical use |
Commercial status |
| Dovonex cream |
Calcipotriene 0.005% |
Plaque psoriasis |
Generic competition |
| Dovonex ointment |
Calcipotriene 0.005% |
Plaque psoriasis |
Generic competition |
| Dovonex scalp solution |
Calcipotriene 0.005% |
Scalp psoriasis |
Limited generic and formulation competition |
| Taclonex |
Calcipotriene 0.005% plus betamethasone dipropionate 0.064% |
Plaque psoriasis |
Branded combination product; generic competition in some forms |
| Wynzora |
Calcipotriene plus betamethasone |
Plaque psoriasis |
Branded foam formulation marketed by Arcutis |
| Generic calcipotriene |
Calcipotriene 0.005% |
Plaque psoriasis |
Multiple manufacturers and distributors |
Dovonex was historically positioned as a prescription nonsteroidal alternative to topical corticosteroids. Its commercial value declined as the market shifted toward combination therapy, higher-convenience formulations, and biologic treatment for moderate-to-severe disease.
When did Dovonex lose exclusivity?
Dovonex lost meaningful market exclusivity after the expiration of its primary U.S. patent protection and the entry of generic calcipotriene products. The original Dovonex patents date from the 1980s and early 1990s, placing the end of ordinary U.S. patent protection well before the 2020s.
The principal exclusivity events were:
| Period |
Event |
Market impact |
| Late 1980s to early 1990s |
Dovonex developed and launched in major markets |
Establishment of topical calcipotriene category |
| 1990s |
U.S. prescription commercialization expanded |
Brand adoption in plaque psoriasis |
| Early 2000s |
Core product patents reached ordinary expiry periods |
Generic development became commercially viable |
| 2000s onward |
Generic calcipotriene products entered or expanded |
Price erosion and formulary substitution |
| 2010s onward |
Combination products and new delivery systems gained attention |
Reduced strategic importance of single-agent Dovonex |
| 2020s |
Mature generic market |
Limited branded pricing power |
The precise patent-expiration date varies by patent, formulation, jurisdiction, and any applicable regulatory extensions. The current commercial question is no longer whether generic entry is legally possible. It is whether a manufacturer can obtain sufficient volume and reimbursement to support production of a low-price topical product.
What patents protected Dovonex?
Dovonex was supported by patents covering the calcipotriene compound, topical compositions, and related pharmaceutical use. The foundational patent estate was developed before current Orange Book listing practices and modern formulation strategies became standard.
The patent categories included:
- Calcipotriene and vitamin D analog chemistry.
- Topical pharmaceutical compositions.
- Cream and ointment vehicles.
- Use of calcipotriene to treat psoriasis and related dermatologic disorders.
- Combination treatment involving calcipotriene and corticosteroids.
The core single-agent Dovonex estate is expired. Later patents covering combination products, specific vehicles, foam systems, packaging, or manufacturing processes did not recreate the original Dovonex exclusivity. Those patents may protect separate commercial products, such as Taclonex or Wynzora, but they do not generally block ordinary generic calcipotriene cream or ointment.
What is the Orange Book status of Dovonex?
The FDA Orange Book identifies approved drug products and associated patent and exclusivity information. Dovonex’s historic Orange Book relevance is limited because its principal patent protection has expired and the product is no longer the center of an active branded exclusivity strategy. FDA records and current product listings should be reviewed by dosage form because calcipotriene products may be listed under generic names or under combination-product trade names rather than as active Dovonex products (U.S. Food and Drug Administration [FDA], n.d.-a).
Dovonex has no remaining new chemical entity exclusivity. Any current market protection would have to arise from a separate product, formulation, combination, device, manufacturing process, or regulatory exclusivity period.
How many patents currently cover Dovonex?
No meaningful unexpired patent estate appears to protect the basic Dovonex calcipotriene cream or ointment franchise in the United States. The number of live patents that may be relevant to a specific generic product depends on:
- The dosage form.
- The formulation vehicle.
- The manufacturing process.
- The product’s packaging or applicator.
- Combination use with betamethasone.
- The target jurisdiction.
A broad patent count would overstate Dovonex protection because patents directed to combination products or newer foam formulations do not necessarily cover generic single-agent calcipotriene.
What formulation patents protect calcipotriene products?
Formulation patents are more commercially relevant than the expired Dovonex compound estate. Calcipotriene is sensitive to formulation conditions, including pH, excipient selection, stability, and compatibility with corticosteroids.
Potentially differentiated formulations include:
- Cream and ointment vehicles with improved stability.
- Scalp solutions.
- Aerosol foams.
- Calcipotriene-betamethasone combinations.
- Formulations that improve cosmetic acceptability or reduce application frequency.
- Vehicle systems designed to support drug delivery through plaques.
Wynzora is an example of a later-generation calcipotriene/betamethasone product using a foam formulation. Its commercial protection is distinct from the original Dovonex estate and depends on its own patents, regulatory approvals, and market positioning. Generic competition against such products may require formulation-specific development rather than simple substitution with calcipotriene cream.
What is the FDA regulatory status of Dovonex?
Calcipotriene is an FDA-approved topical prescription therapy for plaque psoriasis. The FDA has approved generic versions of calcipotriene in relevant topical dosage forms. The agency’s approval pathway for a generic product generally requires pharmaceutical equivalence and bioequivalence or another acceptable demonstration of therapeutic equivalence under the applicable abbreviated new drug application framework (FDA, n.d.-b).
Dovonex differs from biologic psoriasis products because it is a locally applied small-molecule drug. Biosimilar approval is therefore not relevant. A competing calcipotriene product is a generic drug, not a biosimilar.
Regulatory barriers remain for:
- Demonstrating equivalence for semisolid topical products.
- Establishing formulation sameness or acceptable differences.
- Managing stability and preservative systems.
- Producing consistent batches at low cost.
- Meeting FDA manufacturing and quality requirements.
Which companies compete with Dovonex?
Competition occurs across several market layers.
Generic calcipotriene manufacturers
Generic manufacturers compete primarily on price, wholesaler access, pharmacy contracts, and supply reliability. The market may include companies that manufacture directly and companies that market products sourced from contract manufacturers. Product availability can change as companies discontinue low-margin topical lines.
Leo Pharma
Leo Pharma retains historical ownership of the Dovonex franchise and has marketed other dermatology products, including calcipotriene/betamethasone combinations in certain markets. The company’s strategic emphasis has shifted toward a broader dermatology portfolio rather than reliance on legacy Dovonex revenue.
Arcutis Biotherapeutics
Arcutis markets Wynzora, a calcipotriene and betamethasone dipropionate foam for plaque psoriasis. The product competes through vehicle convenience, application experience, and branded promotion rather than through single-agent calcipotriene pricing.
Corticosteroid and combination-product manufacturers
Topical corticosteroids, calcipotriene/betamethasone products, tazarotene, roflumilast, and other topical agents compete for the same treatment decisions. For patients with more extensive or refractory psoriasis, biologics and oral therapies compete with topical treatment at the disease-management level.
What generic entry risks exist for Dovonex?
Generic entry risk is already realized rather than prospective. The principal consequence has been erosion of brand volume and net price. Remaining commercial risks include:
- Continued substitution by low-cost calcipotriene products.
- Pharmacy benefit manager pressure on reimbursement.
- Product discontinuations caused by low margins.
- Loss of physician awareness of the Dovonex brand.
- Patient migration to combination products or newer topicals.
- Limited ability to support sales infrastructure for a mature genericized product.
A manufacturer seeking to enter the market would face modest patent risk for standard calcipotriene cream or ointment, but meaningful execution risk. The key issues are manufacturing economics, supply continuity, distributor discounts, and the cost of securing sufficient prescription volume.
Has Dovonex faced Paragraph IV challenges?
Paragraph IV litigation is not a central current issue for the original Dovonex product. Paragraph IV certifications are most relevant when an ANDA applicant seeks approval before expiration of listed patents. Because the foundational Dovonex patents expired years ago, the product’s genericization has generally proceeded through ordinary patent-expiry dynamics rather than an active branded litigation campaign.
Paragraph IV risk may remain relevant for later calcipotriene products, including patented combinations or specialized delivery systems. A generic applicant challenging a foam, fixed-dose combination, or protected formulation could face a different litigation profile from an applicant seeking approval for standard calcipotriene ointment.
What patent litigation affects Dovonex and calcipotriene products?
There is no well-established current litigation profile comparable to the major patent disputes surrounding blockbuster biologics or oral small molecules. Historical disputes involving calcipotriene products have focused more on generic approval, formulation scope, and combination-product rights than on a continuing dispute over the basic Dovonex compound.
The litigation risk is segmented:
| Product type |
Patent risk |
Commercial implication |
| Generic calcipotriene cream |
Low |
Price competition dominates |
| Generic calcipotriene ointment |
Low |
Supply and reimbursement are central |
| Calcipotriene scalp solution |
Low to moderate |
Smaller market and formulation issues |
| Calcipotriene/betamethasone combination |
Moderate |
Product-specific patents may apply |
| Foam delivery systems |
Moderate to high |
Formulation and device claims may matter |
| Biologic psoriasis products |
Separate legal framework |
Biosimilar and interchangeability issues, not Dovonex issues |
How has Dovonex revenue changed?
Leo Pharma does not report Dovonex revenue as a standalone line item in publicly available corporate financial reporting. The company reports at a portfolio or business level, which prevents a precise product-level revenue series.
The financial trajectory is clear:
Launch and growth phase
Dovonex benefited from clinical differentiation as a nonsteroidal topical psoriasis treatment. Prescription demand expanded as dermatologists adopted vitamin D analog therapy and as the product became established in treatment guidelines and clinical practice.
Maturity phase
Sales growth slowed as the topical psoriasis category became crowded. Corticosteroid combinations, alternative vitamin D analog products, and new delivery systems reduced the brand’s ability to expand through prescription growth alone.
Generic erosion phase
Generic entry reduced average selling prices and shifted volume toward pharmacy substitution. The brand’s revenue likely declined more sharply than prescription demand because generic conversion reduced branded net sales even where total calcipotriene use remained stable.
Current phase
Dovonex is best characterized as a legacy product with limited standalone revenue relevance. Current economic value lies in residual brand recognition, international sales where generic penetration differs, and the broader commercial history of calcipotriene-based dermatology products.
How strong is the Dovonex patent estate?
The patent estate is weak for the original product and stronger only in relation to later differentiated products.
| Dimension |
Assessment |
| Core compound protection |
Expired |
| Standard cream and ointment protection |
Expired or commercially ineffective |
| Brand exclusivity |
Lost |
| FDA regulatory exclusivity |
None for the legacy product |
| Formulation differentiation |
Relevant for newer products |
| Combination-product protection |
Product-specific |
| Manufacturing barriers |
Moderate but manageable |
| Generic launch risk |
Low patent risk; moderate economic execution risk |
| Biosimilar risk |
Not applicable |
A competitive assessment should distinguish patent strength from manufacturing difficulty. Calcipotriene is not difficult to commercialize because of biologic complexity, but semisolid topical production still requires validated processes, stability control, and reliable supply of active ingredient and excipients.
What licensing deals affect Dovonex?
No major current licensing transaction appears to define the Dovonex market. The principal commercial arrangements have historically involved product development, regional commercialization, manufacturing, and distribution rather than a new patent monetization cycle.
Licensing value is higher for:
- New calcipotriene delivery systems.
- Fixed-dose calcipotriene/betamethasone products.
- Dermatology platforms with proprietary vehicles.
- International rights in markets with lower generic penetration.
- Co-commercialization of branded topical products.
The expired single-agent Dovonex estate has limited leverage in a new licensing transaction. Any meaningful deal would likely depend on a differentiated formulation, combination product, geographic rights, or a broader dermatology portfolio.
How does Dovonex compare with newer psoriasis treatments?
| Treatment |
Position versus Dovonex |
Pricing profile |
IP profile |
| Generic calcipotriene |
Direct substitute |
Low |
Weak or expired |
| Calcipotriene/betamethasone |
More potent combination option |
Moderate to high |
Product-specific patents |
| Topical corticosteroids |
Often lower-cost alternative |
Low |
Mature |
| Roflumilast topical |
Newer nonsteroidal option |
Branded |
Active product patents and exclusivity |
| Tapinarof |
Newer nonsteroidal topical |
Branded |
Active branded protection |
| Biologics |
Used for more extensive disease |
High |
Biologic patents and exclusivity |
| Oral TYK2 or other systemic therapies |
Systemic treatment for appropriate patients |
High |
Active branded protection |
Dovonex remains relevant where physicians prefer a nonsteroidal topical or where cost is a primary consideration. Its limitations are slower commercial momentum, generic pricing, and competition from products with stronger convenience or efficacy positioning.
What generic launch scenarios remain?
The most plausible scenarios are:
- Continued low-price generic supply for cream and ointment.
- Periodic manufacturer exits because of weak margins.
- Growth in combination-product substitution where generic calcipotriene/betamethasone is available.
- Stable use in cost-sensitive dermatology channels.
- Limited branded recovery for Dovonex itself.
- Selective opportunity for a differentiated foam, solution, or vehicle.
A new generic entrant would not need to overcome the original Dovonex patent estate. It would need to meet FDA requirements, secure manufacturing capacity, and compete against established low-cost suppliers.
What is the geographic coverage of Dovonex?
Dovonex and calcipotriol products have had international commercial exposure, but brand status varies by country. In the United States, the product is generally understood through the generic name calcipotriene and through combination products. In Europe and other markets, calcipotriol terminology and local brand names are more common.
Geographic market value depends on:
- National generic substitution rules.
- Reimbursement policies.
- Brand-prescribing practices.
- Local patent expiry dates.
- Registration status by dosage form.
- Availability of combination products.
- Dermatology treatment guidelines.
International rights should therefore be analyzed country by country rather than treated as a single global patent estate.
Key Takeaways
- Dovonex is a legacy calcipotriene brand for plaque psoriasis.
- Its core U.S. patent protection has expired, and generic calcipotriene products compete directly.
- Dovonex has no remaining new chemical entity exclusivity.
- Biosimilar risk does not apply because calcipotriene is a small-molecule topical drug.
- Formulation and combination-product patents matter more than the original Dovonex compound patents.
- Leo Pharma does not publicly disclose standalone Dovonex revenue.
- The financial trajectory is one of launch growth, maturity, generic price erosion, and limited residual brand value.
- The strongest commercial opportunities are in differentiated delivery systems and calcipotriene/betamethasone combinations, not ordinary Dovonex cream or ointment.
- Generic entry risk is low from a core-patent perspective but remains meaningful from a manufacturing and reimbursement perspective.
- Newer topical agents, combination products, and biologics constrain Dovonex’s long-term market relevance.
FAQs
Is Dovonex still available by prescription?
Generic calcipotriene remains available by prescription in the United States and other markets. Availability of the Dovonex brand itself varies by country, dosage form, and supplier.
Is calcipotriene the same as Dovonex?
Yes. Dovonex is a historical brand name for calcipotriene, called calcipotriol in many non-U.S. markets.
Can generic calcipotriene replace Dovonex?
For an equivalent approved dosage form, generic calcipotriene is intended to provide the same active ingredient and therapeutic effect. Substitution depends on the product, pharmacy rules, prescriber instructions, and payer policy.
Does Dovonex have biologic competition?
Dovonex does not face biosimilar competition. It competes indirectly with biologics used for moderate-to-severe psoriasis, while remaining more relevant for localized disease treated with topical therapy.
Is Dovonex a growth product for pharmaceutical investors?
No. Dovonex is a mature, genericized product with limited standalone growth potential. Investment value would more likely arise from a differentiated calcipotriene formulation, combination product, or broader dermatology platform.
References
-
U.S. Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products and abbreviated new drug applications. https://www.fda.gov/drugs/drug-approvals-and-databases
-
U.S. Food and Drug Administration. (n.d.-c). Dovonex label information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
Leo Pharma. (n.d.). Dermatology products and company information. https://www.leo-pharma.com/
-
Arcutis Biotherapeutics. (n.d.). Wynzora cream prescribing information. https://www.wynzora.com/
-
National Psoriasis Foundation. (n.d.). Psoriasis treatment options. https://www.psoriasis.org/psoriasis-treatments/
-
U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
